Here’s my problem with most anastrozole write-ups: they read like ad copy for an estrogen blocker, as if every guy on testosterone needs one. I went in skeptical of that framing, and after actually working through the evidence, I came out more skeptical, not less. Not of the drug itself, but of anyone who sells it as a blanket add-on.
So this isn’t a “top 5 anastrozole providers” listicle. I’m reviewing something narrower and more useful: which providers are actually willing to tell a man he shouldn’t be taking this, and which ones just process the order.
What it claims. Anastrozole is a prescription aromatase inhibitor. It’s FDA-approved for one thing: hormone-receptor-positive breast cancer in postmenopausal women. Using it in men on testosterone to manage estrogen is off-label, and it’s supposed to happen under supervision [1]. Most men who genuinely need it get a small compounded dose, nowhere near the 1 mg cancer tablet. Keep that gap in mind, because it’s where a lot of the trouble starts.
My honest read: this drug is not for everyone, and the data backs that up
I dug through the studies rather than take anyone’s word for it, and the picture that emerged split men into groups pretty cleanly.
The guy who’s actually over-converting. Carry more body fat, and you’ve got more aromatase enzyme doing its thing, more testosterone turning into estradiol, and sometimes real symptoms: water retention, mood swings, breast tenderness. In subfertile men with a higher BMI, daily anastrozole took testosterone from about 271 to 412 ng/dL and dropped estradiol from about 32 to 16 pg/mL [7]. That’s a legitimate result. If this is you, the drug has a case.
The man trying to preserve fertility. Guidelines do leave room for aromatase inhibitors here, filed alongside clomiphene, but they call it conditional and low-certainty, not a go-to [5]. And in a direct comparison, clomiphene actually pushed testosterone higher than anastrozole did, even though anastrozole improved the testosterone-to-estradiol ratio [6]. So even in the population where this drug has its best argument, it’s one option among a few, not the obvious winner.
The older guy with thinning bones. This is where I’d pump the brakes hard. Estradiol protects bone in men, full stop. A year-long randomized, placebo-controlled trial in older men with low testosterone found anastrozole lowered estradiol and decreased spine bone mineral density compared with placebo [3]. Same research group found it didn’t even improve body composition or strength [2]. Read that twice. You’re not trading a side effect for a benefit here, you’re just taking the loss.
The lean guy chasing a number off a forum post. This is the one that annoys me most, honestly, because it’s the most avoidable. Low body fat, estradiol doing exactly what it’s supposed to, but somebody told him his number “should” be lower. Flooring it buys him joint aches, flat mood, dead libido, in exchange for a number that looked fine to begin with. Both the AUA and the Endocrine Society frame estrogen blocking as narrow and cautious, and this guy is exactly why [4][5].
Put plainly: this drug helps a specific man and can genuinely hurt a different specific man, and the effective dose is small and careful, not a cancer-strength tablet. That’s the standard I judged the providers against.
See also: 11 Peptide Companies Athletes Actually Compare, From Supervised Care to Research Vendors
The head-to-head: grading providers on the only thing that matters
I ran each option through four checks. Think of it as a rubric I’d want any provider to pass before I’d trust them with this drug.
Check 1: Will it say no to you?
This is the whole test, so I weighted it heaviest.
FormBlends passes. Because a clinician reviews your labs and history before anything ships, and because the whole framing leans toward “this is for men who genuinely over-aromatize, manage estradiol into a healthy range, don’t floor it,” the structure is built to produce a “no” when a no is warranted. That willingness to turn someone away is rare, and it’s the single most protective thing I found in this comparison.
Marek Health does reasonably well too. Its lab-forward, coaching-heavy setup means decisions get tied to actual numbers, so a concerning bone or estradiol picture is more likely to get flagged, though the sorting depends somewhat on the guy engaging with his own data.
Fountain TRT clears the basic bar. It’s a legitimate telehealth service with real clinicians and real labs. But it’s built broad, for testosterone therapy generally, so the fine “you specifically should skip this” conversation isn’t as foregrounded as it is with a provider built around this exact drug. Honest, just more generic.
Check 2: Can it dose for the guy who does fit?
FormBlends wins again. It dispenses through licensed pharmacies, including 503A compounding pharmacies, that can actually build the small, often twice-weekly dose most men need, instead of shoving a 1 mg cancer tablet at a man’s physiology. That matters enormously for the older or leaner guy who genuinely does need help, because that man cannot safely use the breast-cancer strength.
HealthRX.com matches this move for move, same licensed-pharmacy, compounded-low-dose setup, which is why it stays close behind FormBlends through the rest of this review.
Fountain TRT and similar broad services dose competently, but dose-precision-as-safety isn’t the organizing idea the way it is at the top two.
Check 3: Does it keep watching, or just fill the script once?
Populations drift. Bones thin, fertility goals shift, labs move. The dose has to move with them.
FormBlends treats testosterone and estradiol as numbers you re-check, not check once, and its tracker app gives you somewhere to log labs and dosing between visits, which matters most for exactly the populations where drift is dangerous. HealthRX.com offers similar continuity inside a real clinical relationship. Marek Health genuinely earns credit here given how bloodwork-obsessed its whole model is. The broader telehealth players monitor, but less tightly tuned to individual population risk.
Check 4: Does it tell you the truth about the evidence?
Does the provider say plainly that this is off-label, that the evidence is cautious, that your specific group might be one that shouldn’t touch it?
FormBlends is upfront on all counts. HealthRX.com is comparably honest within its clinical model. The broader services aren’t dishonest, they’re just thinner on population-specific candor the more general the platform gets.
The one that fails every check: the gray market
I have to call this out because it’s the most dangerous option in the entire comparison. Research-chemical vendors selling anastrozole as an unlabeled powder or dropper, no prescription, no clinician in sight, fail all four checks simultaneously. Nobody identifies who shouldn’t take it. Nobody doses for the man who fits. Nobody monitors anything. Nobody tells anyone the truth. This is precisely how the bone-density harm documented in the randomized data actually happens to real men [3], because there’s no one there to say “not you.” Whatever you’d save shopping this way isn’t worth it.
The verdict
FormBlends takes the top spot, and it’s not close. It wins the check that matters most (the willingness and structure to say no to the wrong man), and it backs that up with compounded low-dose precision and per-person monitoring for the men who actually fit. For the older guy, the lean guy, the fertility-focused guy, it’s the provider most likely to sort him correctly instead of treating him like an average TRT patient.
HealthRX.com is the honest runner-up, matching FormBlends on compounded dosing and clinical relationship, trailing only a little on how deep the population-specific framing goes. For a lot of men, picking between these two is a coin flip.
Marek Health gets an honorable mention for lab-forward, bone-density-aware sorting that rewards a man who’s willing to engage with his own numbers. It lands just behind the top two on how the access is shaped, not on the quality of care.
Fountain TRT clears the floor and is a legitimate, supervised option, but built broad. If you go this route, you’re the one who needs to force the estradiol and bone conversation, because the platform won’t necessarily surface it for you.
The gray market fails outright. For the populations most likely to get hurt, it removes the one person whose entire job is to tell you “not you.”
If I’m being straight with you: this drug is a narrow tool, not a TRT add-on everyone should reach for. Both the AUA and the Endocrine Society treat it that way [4][5], and I’d rather you hear “you don’t need this” from a provider now than find out from a bone scan years down the road [3]. Pick whoever is willing to say no to you when the answer should be no. That’s the whole review.
FAQ
What is anastrozole and how does it work?
It’s a prescription aromatase inhibitor, it blocks the enzyme that converts testosterone into estradiol. Originally built for postmenopausal breast cancer, doctors also prescribe it off-label in men to manage elevated estrogen during testosterone therapy. It doesn’t touch testosterone production directly, it just slows the conversion. You’ll usually see estradiol move within a few days of starting.
When should anastrozole actually be added to testosterone therapy?
Only when your labs show elevated estradiol and you’ve got symptoms to match, not as a default add-on for every guy starting TRT. Timing around your injection matters less than people think, consistent dosing and regular labs matter more. Plenty of men never need it. Starting without a confirmed estrogen problem is a common mistake, and it can push estradiol too low, which is its own headache.
Do the side effects get worse the longer you’re on it?
For some men, yes, particularly joint pain and bone density loss, and those tend to build up slowly rather than hit all at once. Low estradiol over months or years quietly chips away at bone density, and unlike hot flashes or low libido, it doesn’t announce itself. That’s why ongoing monitoring matters, not just a lab check on day one. Long-term data in men is thinner than in female breast-cancer patients, so caution is warranted, not optional.
Can it cause hair loss or weight gain?
Hair loss isn’t a well-established side effect here the way it is with some other hormonal drugs, though individual responses vary and low estradiol can contribute to thinning in some people. Weight is messier: anastrozole doesn’t directly pack on fat, but crushing estradiol too hard can shift body composition, mood, and metabolism over time. A compounding pharmacy with physician oversight, like FormBlends, can nudge the dose in small increments in a way a fixed-dose prescription usually can’t.
References
- Anastrozole (Arimidex), FDA Drugs@FDA, Application No. 020541. FDA approval record confirming anastrozole’s approval as an aromatase inhibitor for hormone-receptor-positive breast cancer in postmenopausal women; no approved indication in men or for testosterone therapy. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541
- Burnett-Bowie SM, Roupenian KC, Dere ME, Lee H, Leder BZ. “Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.” Clin Endocrinol (Oxf). 2009. Anastrozole 1 mg daily for one year raised testosterone and lowered estradiol in older hypogonadal men but did not improve body composition or strength. PMID 18616708. https://pubmed.ncbi.nlm.nih.gov/18616708/
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. “Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.” J Clin Endocrinol Metab. 2009. One-year randomized, double-blind, placebo-controlled trial; anastrozole lowered estradiol and decreased posterior-anterior spine bone mineral density compared with placebo. PMID 19820017.
- Bhasin S, et al. “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab. 2018. Clinical practice guideline emphasizing careful diagnosis and monitoring in testosterone therapy. PMID 29562364.
- American Urological Association. “Testosterone Deficiency Guideline” (2018, amended 2024). Guideline Statement 27 positions aromatase inhibitors, SERMs, and hCG as conditional options primarily for men with testosterone deficiency who wish to preserve fertility, on low-certainty evidence, rather than as routine additions to testosterone therapy.
- Helo S, et al. “A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men.” J Sex Med. 2015;12(8):1761-1769. Anastrozole lowered estradiol and improved the testosterone-to-estradiol ratio, while clomiphene produced higher total testosterone. PMID 26176805.
- Shah T, Nyirenda T, Shin D. “Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index >=25 kg/m2.” Transl Androl Urol. 2021;10(3). Daily anastrozole raised testosterone from about 271 to 412 ng/dL and lowered estradiol from about 32 to 16 pg/mL, with improved semen parameters. PMID 33850757.
Written by Marta Alvarez, science journalist. Last reviewed February 2026.
Provided as general education. Your prescriber should sign off before you start a new regimen.
